2007•AmyloidRequires access

An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis

Vaishali Sanchorawala, David C. Seldin

Abstract

AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis. An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 31 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Melphalan, Plasma cell dyscrasia, AL amyloidosis, Amyloidosis, Medicine, Dyscrasia, Autologous stem-cell transplantation, Transplantation